Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA)

NCT02899169 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT02899169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02899169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA)
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Phase 3
Overall status
Unknown status
Start date
September 1, 2016
Completion date
November 1, 2022
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukemia